Kornimate/medical-research-clean huggingface dataset:
chronic kidney disease at northeast taiwan: biomarker and multidisciplinary care

Conditions: Chronic Kidney Disease

Summary: ckd is a global endemic disease with increased comorbidities and mortality. the prevalence and the incidence of the end-stage renal disease (esrd) are extremely high in taiwan. early diagnosis of disease and proper management remain challenging. the aims of this study are: 1. explore risk factors associated with ckd 2. establish multidisciplinary care model for ckd patients 3. development cost-effective clinical care pathway for ckd 4. provide bio-specimen repository for future study

ckd is a global endemic disease with increased comorbidities and mortality. the prevalence and the incidence of the end-stage renal disease (esrd) are extremely high in taiwan. early diagnosis of disease and proper management remain challenging. the aims of this study are: 1. explore risk factors associated with ckd: demographic, social and genetics factors 2. establish multidisciplinary care model for ckd patients 3. development cost-effective clinical care pathway for ckd 4. provide bio-specimen repository for future study: serum, pbmc, urine and stool

Eligibility criteria:
inclusion criteria: * subjects visiting outpatient clinics of nephrology of chang gung memorial hospital exclusion criteria: * patient receiving dialysis or transplantation * unwilling to participate

Keywords: risk factors omics multidisciplinary care
study of the effects of pantoprazole on levels of prescribed psychiatric medications

Conditions: Psychotic Disorders; Gastroesophageal Reflux

Summary: the purpose of this 9-day study is to determine if: 1. pantoprazole modifies the steady-state plasma concentrations of orally administered psychotropic medications including valproic acid, lithium, and second-generation antipsychotics (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) 2. serum gastrin levels change within a week of starting or stopping pantoprazole

individuals with psychiatric diagnoses may be predisposed to gastroesophageal reflux disease because of the widespread use of alcohol, cigarettes, and certain psychotropic drugs in this population. consequently, they are often prescribed proton pump inhibitors. to our knowledge, no studies have been conducted to determine the effects of proton pump inhibitors on plasma levels of psychotropic drugs. the present clinical study will assess the effects of pantoprazole on the pharmacokinetics of valproic acid, lithium, and second-generation antipsychotics.

Eligibility criteria:
inclusion criteria: * participants must be fluent in english * participants with a psychiatric diagnosis and currently treated with one or more of the following medications: valproic acid, lithium, or a second-generation antipsychotic (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone) * participants on a stable dose of valproic acid, lithium, and/or a second-generation antipsychotic for a sufficient period of time that ensures they are at steady state * participants with symptoms of gastroesophageal reflux disease (gerd) that would benefit from treatment with pantoprazole or participants currently treated for gerd with pantoprazole for more than 8 weeks and are currently symptom free. exclusion criteria: * participants that are hypersensitive to pantoprazole * pregnant or lactating women * women of childbearing age not using reliable contraception * any postsurgical complications of the gastrointestinal tract that might impair absorption * clinically relevant abnormalities of laboratory parameters * participants treated with another acid suppressing agent (e.g., h2 receptor antagonists, antacids, alginates, etc) * participants treated with atazanavir, delavirdine, erlotinib, nelfinavir, and/or posaconazole

Keywords: drug interactions pantoprazole proton pump inhibitors psychotropic drugs antipsychotic agents aripiprazole asenapine clozapine lurasidone olanzapine 9-hydroxy-risperidone quetiapine risperidone ziprasidone valproic acid lithium gastrins psychotic disorders gastroesophageal reflux
key to improve diagnosis in aspiration pneumonia

Conditions: Infectious Pneumonia; Coma

Summary: to evaluate the diagnostic performance of amylase assay performed from bronchial alveolar fluid to differentiate aseptic chemical inhalation pneumonitis from an infectious inhalation pneumonitis in comatose patients with intubated ventilation for less than 24 hours.

validation of the potential diagnostic performance of amylase assay compared to gold standard in diagnosis of infectious inhalation pneumonia of the comatose patient enabling the realization of a multicentric study using this innovative method in a diagnostic strategy with the objective of reducing the consumption of antibiotics.

Eligibility criteria:
inclusion criteria: * patient intubated ≤ 24 hours for unconsciousness (stroke, meningitis, drug intoxication, metabolic disorders, epilepticus, cardiac arrest). * inhalation table with hypoxemic acute respiratory insufficiency post-consciousness + chest x-ray revealing one or more compatible infiltrates + t °\> 38 ° c). * age ≥18 years * patient affiliated to the social security system. * no opposition obtained exclusion criteria: * immunocompromised patient. * cardiorespiratory arrest requiring therapeutic hypothermia. * pneumopathy nosocomiale (pneumopathy beginning\> 48h after hospital admission). * infectious pneumonia in the previous 30 days. * previous hospitalization in the previous 30 days. * patient under antibiotic at baseline. * bacteremia. * mechanical ventilation begun before unconsciousness. * report pa02 / fi02 \<80. * patient under curatorship and / or guardianship.

Keywords: bronchoalveolar lavage amylase assay aspiration pneumonia
pomegranate to reduce maternal and fetal oxidative stress and to improve outcome in pregnancies complicated with preterm premature rupture of membranes

Conditions: PPROM

Summary: preterm premature rupture of membrane is associated with increased oxidative stress and inflammatory process, enhancing the activity or the availability of antioxidants may modulate the inflammatory response associated with pprom, thereby reducing oxidative stress and the risk to the fetus. in this study the investigators sought to determine the effects of pomegranate 1. on the patients (maternal and fetal) oxidative stress and inflammation associated with pprom. 2. on the time interval from pprom to delivery and on the patients (fetal )ph and apger scores

in this study the investigators sought to determine the effects of pomegranate 1. on the patients (maternal and fetal )oxidative stress and inflammation associated with pprom. 2. on the time interval from pprom to delivery and on the patients (fetal )ph and apger scores

Eligibility criteria:
inclusion criteria: * pregnant patients * admitted with pprom * between 24-32 weeks of gestation exclusion criteria: * women with contractions * abruption * monochorionic multiple pregnancy * abnormal (non-reassuring) cardiotocogram * meconium-stained amniotic fluid * signs of intrauterine infection * major fetal anomalies * hemolysis * elevated liver enzymes * low platelets (hellp syndrome); or severe preeclampsia.

Keywords: pprom pregnancy pomegranate oxidative stress
malawi international center of excellence in malaria research school-based cohort

Conditions: Malaria; Malaria,Falciparum; Anemia

Summary: a school-based, prospective, cohort study was conducted to evaluate the epidemiology of p. falciparum (pf) infections in school-age children and determine the impact of the screen-and-treat approach on pf infection and anemia prevalence among students in two different transmission settings. investigators aimed to evaluate how frequently malaria rapid diagnostic tests (mrdts) fail to detect low-parasite-density infections as well as whether low-density infections contribute to the burden and health consequences of pf infection in school-age children and whether they contain gametocytes, the parasite stage required for transmission from humans to mosquitos.

students were enrolled in four schools in southern malawi in the rainy (march-may) and dry season (sept-nov) of 2015. 15 students per grade-level (grades 1-8), were invited to participate. following enrollment, students were evaluated at baseline for screening-and-treatment, and followed-up 1, 2 and 6 weeks later. at each follow-up visit, a blood sample was obtained for microscopy and molecular detection of parasites and students were interviewed about bed net use the night prior, current or recent illness, and use of antimalarial treatment. at the final visit, a mrdt and hemoglobin test were repeated, and parents were interviewed and portable medical records ("health passports") were reviewed to identify intercurrent fever or malaria treatment.

Eligibility criteria:
inclusion criteria: * randomly selected student at a participating school exclusion criteria: * parent or guardian not available for consent * age \ = 16 years * known allergy or adverse reaction to lumefantrine-artemether * child will not attend this school during the time of the survey * for the dry season survey (sept-oct 2015), participants in the rainy season survey (april-may 2015)

Keywords: cohort screen and treat artemether-lumefantrine
acupuncture for plantar fasciosis in the primary care setting

Conditions: Plantar Fascitis

Summary: the purpose of this study is to determine if the addition of acupuncture to a standard of care prescribed exercise program is more effective at improving pain and function in adult patients with plantar fasciosis.

investigators are studying whether a specific acupuncture protocol, when added to the standard of care treatment, can improve pain and function in adults with plantar fasciosis. investigators hypothesize that there will be a significant improvement in both pain and functional outcomes, both acutely and over time, in the experimental group compared to the control group. investigators will measure foot pain immediately prior to treatment (baseline), immediately after the initial treatment and at 2 weeks, 4 weeks, and 3 months. the foot function index revised short form will be used during the same intervals to evaluate foot function. at 3 months, patients in the non-acupuncture group will cross-over into the acupuncture group if still experiencing pain.

Eligibility criteria:
this study is being conducted at a military installation. you must have military insurance in order to participate in this study. inclusion criteria: male and female dod beneficiaries, age 18 years or older, who have been diagnosed with plantar fasciitis/fasciosis or patients meeting criteria of pain in the bottom of the foot/heel with first steps in the morning \& tender to palpation over the medial calcaneal tubercle (where the plantar fascia inserts). those with acute and chronic diagnoses will be included. exclusion criteria: * pregnant * absence of leg * active cellulitis of lower extremity * prior surgery for plantar fasciitis * steroid injections in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subjects will be offered to be involved in the study after they have completed a 12 week wash out period. * any regenerative therapy to include proliferation therapy or platelet rich plasma therapy in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subject will be offered to be involved in the study after they have completed a 12 week wash out period. * botox injections for plantar fasciitis injections in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subject will be offered to be involved in the study after they have completed a 12 week wash out period. * use of anticoagulants * if they have every had any prior acupuncture for plantar fasciitis using the defined kb-2 points

Keywords: acupuncture plantar fasiosis
a trial assessing the outcome of celecoxib administration versus placebo following anterior cruciate ligament (acl) reconstruction

Conditions: Pain

Summary: the aim of this study is to directly compare the clinical outcomes of both the celecoxib and placebo groups following anterior cruciate ligament (acl) reconstruction. the study will have short and long term goals. validated outcome measures will aim to quantify pain control at 2 weeks after surgery, as well as knee function at 2 year follow-up. groups will be compared using pain control scales, and functional knee outcome scores. the first null hypothesis tested by this study is that the celecoxib group experiences equal pain control compared with the placebo group. the second null hypothesis is that no knee function difference will be found between the celecoxib and placebo groups.


Eligibility criteria:
inclusion criteria: * any patient 18 years and over undergoing primary anterior cruciate ligament reconstruction with hamstring grafts will be considered for this study. exclusion criteria: * patients will be excluded if they have bilateral acl injuries, require revision acl reconstruction, require meniscus repair, have multiple ligament injuries, gross osteoarthritis, significant clinical malalignment or if they cannot attend appropriate follow-up. other exclusion criteria will include use of a regional block during the surgery, a diagnosis of esophageal, gastric, or duodenal ulceration, hepatic disease, renal disease, hypertension, hypersensitivity to celecoxib, known allergic-type reactions to sulfonamides, known allergies to asa or other nsaids, inflammatory bowel disease or hyperkalemia

Keywords: primary acl reconstruction with a hamstring graft
eliminate coronary artery disease

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine whether pharmacologic lowering of low density lipoprotein cholesterol (ldl), initiated in healthy young to middle aged adults can eliminate or markedly reduce the composite endpoint of incident all cause mortality, myocardial infarction, stroke or coronary revascularization.


Eligibility criteria:
inclusion criteria: * men 35-50 years of age * women 45 - 59 years of age (must be sterile or \>2 years postmenopausal) * ldl cholesterol greater than 1.8 mmol/l (70 mg/dl) based on testing performed within 1 year * one risk factor for coronary heart disease other than lipid abnormality: * obesity and hypertension \[bp \>140 mmhg systolic and waist circumference \> 100 cm in men and \>90 cm in women\] * family history of premature myocardial infarction \[\<60 years\] * south asian ethnic history * currently smoking exclusion criteria: * currently taking cholesterol lowering medication * qualify for cholesterol lowering medication based on current guidelines * significant renal dysfunction (creatinine clearance \<30 ml/min) * significant hepatic dysfunction (ast/alt \>2.0 times upper limit of normal) * active malignancy * diabetes * progressive or terminal illness, or other condition in which subject is unlikely to survive the study period * known allergy, hypersensitivity (anaphylaxis) ar adverse reaction to any statin * participation in a clinical trial (except observational studies) within previous 30 days * received any investigation product within 30 days prior to participation in this clinical trial * previously enrolled in this clinical trial

Keywords: atorvastatin coronary artery disease myocardial infarction stroke revascularization
effect of nonsurgical periodontal treatment on apelin and oxidative stress levels

Conditions: Periodontitis

Summary: periodontitis is a multifactorial, chronic inflammatory disease triggered by microorganisms in the dental biofilm. the limited data of clinical periodontal measurements in the diagnosis of periodontitis have led to the search for more reliable biomarkers that can be used in the diagnosis and follow-up of periodontal diseases. apelin is another adipokine that has been investigated in a small number of studies so far; its receptor (apelin reseptor (apj)) was first identified in 1993 and later isolated as a molecule in 1998. studies have focused on this form of apelin-13 due to its high biological activity. although apelin-13 is considered the most biologically active form, it has been shown that apelin-36 has a much higher binding affinity to apj than apelin-13. periodontitis is the most common cause of tooth loss in adults, and is associated with systemic conditions such as metabolic syndrome, diabetes mellitus, and cardiovascular disease. the elucidation of these possible interactions has been the focus of many studies. apelin is associated with insulin secretion, as well as its effects on lipid and glucose metabolism. studies in both humans and animals have shown that type 2 diabetes and obesity are typically associated with increased plasma apelin levels. based on this observation, recent studies have shown that salivary and serum apelin levels are higher in individuals with chronic periodontitis and type 2 diabetes compared to healthy individuals. considering all this information, the investigators considered that apelin may be a biomarker for periodontal diseases due to its inflammation-regulating effects as a result of the change in gingival crevicular fluid (gcf) apelin-13, apelin-36 and total oxidant status (tos)/total antioxidant status (tas) levels compared to the initial level after non-surgical periodontal treatment in systemically healthy and periodontitis individuals, considering the relationship of adipokines with periodontal disease in this study.


Eligibility criteria:
inclusion criteria: * being systemically healthy * not smoking * not using anti-inflammatory drugs in the last 3 months, antibiotics and systemic corticosteroids in the last 6 months * not being pregnant or lactating * not having received periodontal treatment in the last 6 months * having at least 20 teeth in the mouth * being diagnosed with periodontitis (stage 1-2 and stage 3-4) by the researcher working groups will be formed based on the 2017 periodontal disease classification exclusion criteria: being periodontally healthy having systemic disease being pregnant and lactating smoking having periodontal treatment in the last 6 months having fewer than 20 teeth
evaluating safety and efficacy of tol101 induction versus anti-thymocyte globulin to prevent kidney transplant rejection

Conditions: End Stage Renal Disease; Renal Transplant

Summary: induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response. in general, induction therapy is associated with better outcomes compared to the absence of induction therapy. however, currently used induction agents, some of which are not labeled or indicated for induction therapy in transplantation, have drawbacks related to long-term immune system suppression increasing susceptibility to opportunistic infections or malignancies, and other immune-mediated side effects. an unmet medical need exists for a more specific approach to prevent acute organ rejection, without unnecessarily exposing the patient to non-specific or open-ended immune suppression, which may exacerbate the risks of infections and malignancies. tol101 is a novel antibody that targets a very specific immune cell type that is critical in the acute organ rejection response. in this two-part study, tol101 will be evaluated for the prophylaxis of acute organ rejection when used as part of an immunosuppressive regimen that includes steroids, mmf, and tacrolimus in first time kidney transplant recipients. this study will test the hypothesis that a more specific approach (with tol101) to prevention of acute organ rejection may provide similar or better efficacy than the currently used induction antibodies (such as anti-thymocyte globulin or thymoglobulin) while carrying fewer risks in terms of opportunistic infections, malignancies and adverse effects.


Eligibility criteria:
inclusion criteria: * recipient of a primary renal transplant from a living or standard criteria cadaveric donor * male or female 18-60 years of age * recipient with a pra \< 20% exclusion criteria: * previous solid organ transplant * recipient of hla-identical kidney allograft transplant * recipient of an abo incompatible donor kidney * known hiv infection or other major infection * history of malignancy within 3 years (excluding treated basal cell or squamous cell carcinoma of the skin) prior to enrollment * history of tuberculosis * recipient with cardiovascular disease * treatment with immunosuppressive medications within 1 month prior to enrollment * known or suspected allergy to mice * pregnant or lactating * unable or unwilling to participate in all required study activities for the duration of the study (6 months)

Keywords: kidney renal transplant kidney transplant kidney failure induction monoclonal antibody t cell anti-rejection immunosuppression
risk of nerve damage after administration of local anesthesia

Conditions: Inferior Alveolar Nerve Injuries

Summary: this research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for inferior alveolar nerve block (ianb). a randomized controlled clinical trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and lidocaine 2%. the type of la will be concealed to the operator, investigators and assessors. the patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.


Eligibility criteria:
inclusion criteria: * patients with age between 18-55 years old * patients need ianb * healthy patient exclusion criteria: * medical conditions * allergies * medications * pregnancy and breastfeeding * inability to provide informed consent * specific dental or medical history.
litramine in weight maintenance

Conditions: Weight Maintenance; Overweight; Obese

Summary: the effect of litramine on weight loss has previously been studied during a 12-week intervention period with promising results. the present study looks into the effect of weight maintenance using litramine following initial weight loss, for a longer period of 24 weeks.


Eligibility criteria:
inclusion criteria: * documented weight loss, achieved over the last 3 to 6 months either from participation in weight loss clinical trials or weight loss regimens, of at least 3% at the point of screening * bmi 25-35 before initial weight loss * documented compliance (according to the investigator's judgement) to previous weight loss clinical trials/ regimens exclusion criteria: * known sensitivity to the ingredients of the device (citric acid, acacia or fabaceae family) * bmi \< 18.5 * presence of other factor(s) that, in the investigator's judgement, should preclude subject participation

Keywords: weight maintenance overweight obese weight management